San Francisco, CA, United States of America

Angelica Medina-Selby

USPTO Granted Patents = 30 (Patent Applications = 4)

CIPO Patents = 5

EPO Patents = 6 (Patent Applications = 6)

Average Co-Inventor Count = 4.6

ph-index = 8

Forward Citations = 208(Granted Patents)

Location History:

Emeryville, CA (US) (2009 - 2016)
San Francisco, CA (US) (1992 - 2020)

Company Filing History:

13 out of 245

Novartis Vaccines & Diagnostics, Gmbh

Ortho-Clinical Diagnostics, Inc

patents

5. 1 out of 28

Grifols Worldwide Operations Limited

7. 1 out of 832,912

Other

patents

where one patent can have more than one assignee

Years Active: 1992-2020

Loading Chart...

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10753939 - HCV NS4a/modified NS3 polypeptides and uses thereof (2020-08-25),

2. 10287324 - Norovirus derived immunogenic compositions and methods (2019-05-14),

3. 10267803 - HCV NS4A/modified NS3 polypeptides and uses thereof (2019-04-23),

4. 10065994 - Norovirus derived immunogenic compositions and methods (2018-09-04),

5. 9744228 - Method for generating a parvovirus B19 virus-like particle (2017-08-29),

6. 9428739 - Norovirus and Sapovirus antigens (2016-08-30),

7. 8475808 - Immunogenic reagents from west nile virus (2013-07-02),

8. 8216590 - HCV fusion polypeptides (2012-07-10),

9. 8142793 - Norovirus and Sapovirus antigens (2012-03-27),

10. 8124104 - Norovirus and sapovirus antigens (2012-02-28),

11. 8119146 - Expressing hepatitis B virus surface antigen for vaccine preparation (2012-02-21),

12. 8119145 - Methods for producing norovirus VLPS (2012-02-21),

13. 7888004 - HCV non-structural polypeptide (2011-02-15),

14. 7871625 - HCV multiple epitope fusion antigens with modified proteolytic cleavage sites and uses thereof (2011-01-18),

15. 7807430 - GSK3 polypeptides (2010-10-05),

Title: The Innovative Contributions of Angelica Medina-Selby in Biotech

Introduction: Angelica Medina-Selby is a prominent inventor based in San Francisco, CA, renowned for her groundbreaking work in the biotechnology sector. With a remarkable portfolio of 30 patents, she has made significant strides in the field of viral research, particularly focusing on hepatitis C and norovirus. Her inventions have contributed to the development of novel immunotherapeutic solutions, showcasing her expertise and commitment to advancing medical science.

Latest Patents: Among her latest patents are two notable innovations. The first patent is for "HCV NS4a/modified NS3 polypeptides and uses thereof," which describes modified hepatitis C virus polypeptides, retaining conformational epitopes crucial for immunoassays. The second patent involves "Norovirus derived immunogenic compositions and methods," focusing on chimeric norovirus VP1 proteins that integrate elements from two norovirus strains to enhance immunogenicity. This invention includes nucleic acids encoding the chimeric proteins, virus-like particles, and immunogenic compositions.

Career Highlights: Angelica's impressive career includes working with leading biotech firms such as Novartis Vaccines & Diagnostics and Chiron Corporation. Her contributions in these roles have facilitated the development of innovative vaccines and diagnostic tools, vital for combating viral infections.

Collaborations: Throughout her career, Angelica Medina-Selby has collaborated with esteemed colleagues in the field. Notable professionals she has worked alongside include Doris Guenzi Coit and Michael Houghton, whose combined efforts have propelled advancements in viral research and vaccine development.

Conclusion: Angelica Medina-Selby's extensive work and prolific patent portfolio underscore her vital role in the biotechnology sector. Her innovative inventions continue to pave the way for new treatments and diagnostics, demonstrating her profound impact on global health initiatives.

This text is generated by artificial intelligence and may not be accurate.